Silo Pharma (SILO) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Silo Pharma is the larger company by market cap ($3.7 million vs $3.4 million), about 1.1 times the size. XTL Biopharmaceuticals converts more of its revenue into profit, with a net margin of -227.7% versus -5863.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SILO | XTLB |
|---|---|---|
| Share price | $1.71 | $1.37 |
| Market cap | $3.69M | $3.37M |
| 1-day change | -9.04% | -5.84% |
| EPS (TTM) | $-2.26 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.10K | $451.00K |
| Revenue growth (YoY) | 0.00% | — |
| Net income (latest FY) | $-4.23M | $-1.03M |
| Gross margin | 38.57% | 0.67% |
| Operating margin | -5936.95% | -481.60% |
| Net margin | -5863.50% | -227.72% |
| 52-week high | $10.43 | $5.64 |
| 52-week low | $1.10 | $1.37 |
| Distance from 52-week high | -83.60% | -75.71% |
| Average volume | 65.47K | 6.58K |
| Shares outstanding | 2.16M | 2.46M |
| Employees | 3 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XTL Biopharmaceuticals is more profitable, keeping -227.7 cents of every revenue dollar as net income versus -5863.5 cents for Silo Pharma.
About Silo Pharma
SILO stock →Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
SILO vs XTLB FAQ
Which is bigger, Silo Pharma or XTL Biopharmaceuticals?
Silo Pharma (SILO) is larger, with a market capitalization of $3.69M compared with $3.37M for XTL Biopharmaceuticals (XTLB).
Are Silo Pharma and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.